As many as 80% of patients who are candidates for preventive treatments for migraine headaches could be helped by these treatments, the author of new guidelines issued by the American Academy of Neurology told Formulary.
As many as 80% of patients who are candidates for preventive treatments for migraine headaches could be helped by these treatments, the author of new guidelines issued by the American Academy of Neurology (AAN) told Formulary.
However, the study’s author, Stephen D. Silberstein, MD, FACP, FAHS, Jefferson Headache Center at Thomas Jefferson University in Philadelphia, said that most of the patients who could benefit from the treatments recommended by the guidelines aren’t taking them.
The reasons, he said, include:
Not enough people know that their headaches would be diagnosed as migraines.
Patients are not aware of the treatments that are available.
Patients have taken the wrong dosing previously and either the treatment worked too slowly or they suffered side effects.
The guidelines on migraine treatments were announced at the AAN’s annual meeting in New Orleans and were published in the April 24 print issue of Neurology.
Researchers reviewed all available evidence on migraine prevention, according to a news release. They found that the following prescription drugs are effective for migraine prevention:
Seizure drugs divalproex sodium, sodium valproate, and topiramate.
Beta-blockers metoprolol, propranolol, and timolol.
The most effective over-the-counter (OTC) treatment is the herbal preparation Petasites, also known as butterbur. Other OTC treatments that were found to be likely effective are the nonsteroidal anti-inflammatory drugs fenoprofen, ibuprofen, ketoprofen, naproxen and naproxen sodium, subcutaneous histamine as well as the complementary treatments magnesium, MIG-99 (feverfew), and riboflavin.
Patients using the OTC and complementary treatments should still see their physicians for follow-ups, Dr Silberstein said.
“Migraines can get better or worse over time, and people should discuss these changes in the pattern of attacks with their doctors, and see whether they need to adjust their dose or even stop their medication, or switch to a different medication,” Dr Silberstein said in the news release.
Coalition promotes important acetaminophen dosing reminders
November 18th 2014It may come as a surprise that each year Americans catch approximately 1 billion colds, and the Centers for Disease Control and Prevention estimates that as many as 20% get the flu. This cold and flu season, 7 in 10 patients will reach for an over-the-counter (OTC) medicine to treat their coughs, stuffy noses, and sniffles. It’s an important time of the year to remind patients to double check their medicine labels so they don’t double up on medicines containing acetaminophen.
Support consumer access to specialty medications through value-based insurance design
June 30th 2014The driving force behind consumer cost-sharing provisions for specialty medications is the acquisition cost and not clinical value. This appears to be true for almost all public and private health plans, says a new report from researchers at the University of Michigan Center for Value-Based Insurance Design (V-BID Center) and the National Pharmaceutical Council (NPC).
Management of antipsychotic medication polypharmacy
June 13th 2013Within our healthcare-driven society, the increase in the identification and diagnosis of mental illnesses has led to a proportional increase in the prescribing of psychotropic medications. The prevalence of mental illnesses and subsequent treatment approaches may employ monotherapy as first-line treatment, but in many cases the use of combination of therapy can occur, leading to polypharmacy.1 Polypharmacy can be defined in several ways but it generally recognized as the use of multiple medications by one patient and the most common definition is the concurrent use of five more medications. The presence of polyharmacy has the potential to contribute to non-compliance, drug-drug interactions, medication errors, adverse events, or poor quality of life.
Medical innovation improves outcomes
June 12th 2013I have been diagnosed with stage 4 cancer of the pancreas, a disease that’s long been considered not just incurable, but almost impossible to treat-a recalcitrant disease that some practitioners feel has given oncology a bad name. I was told my life would be measured in weeks.